Schonfeld Strategic Advisors’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-242,952
| Closed | -$3.18M | – | 2206 |
|
|
2025
Q4 | $3.18M | Buy |
+242,952
| New | +$2.9M | 0.01% | 718 |
|
|
2024
Q4 | – | Sell |
-79,205
| Closed | -$872K | – | 1999 |
|
|
2024
Q3 | $872K | Buy |
+79,205
| New | +$881K | 0.01% | 1207 |
|
|
2024
Q2 | – | Sell |
-20,820
| Closed | -$293K | – | 2143 |
|
|
2024
Q1 | $293K | Sell |
20,820
-15,280
| -42% | -$190K | ﹤0.01% | 1657 |
|
|
2023
Q4 | $277K | Sell |
36,100
-11,400
| -24% | -$63K | ﹤0.01% | 1450 |
|
|
2023
Q3 | $354K | Buy |
47,500
+1,000
| +2% | +$8.53K | ﹤0.01% | 1295 |
|
|
2023
Q2 | $387K | Sell |
46,500
-6,337
| -12% | -$73.1K | ﹤0.01% | 1312 |
|
|
2023
Q1 | $703K | Buy |
52,837
+15,737
| +42% | +$213K | 0.01% | 1063 |
|
|
2022
Q4 | $552K | Buy |
+37,100
| New | +$383K | ﹤0.01% | 1471 |
|
|
2022
Q2 | – | Sell |
-11,500
| Closed | -$77K | – | 2521 |
|
|
2022
Q1 | $77K | Buy |
+11,500
| New | +$68.5K | ﹤0.01% | 2281 |
|
|
2021
Q1 | – | Sell |
-7,933
| Closed | -$102K | – | 1784 |
|
|
2020
Q4 | $102K | Buy |
7,933
+5,600
| +240% | +$99.8K | ﹤0.01% | 1448 |
|
|
2020
Q3 | $86K | Buy |
+2,333
| New | +$92.5K | ﹤0.01% | 1281 |
|
|
2016
Q4 | – | Sell |
-333
| Closed | -$123K | – | 543 |
|
|
2016
Q3 | $123K | Buy |
+333
| New | +$87.7K | 0.02% | 390 |
|
Schonfeld Strategic Advisors's ATXS Position: Q1 2026 in Review
Schonfeld Strategic Advisors sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 242,952 shares — an estimated $3.18M sold.
Schonfeld Strategic Advisors first reported a position in ATXS in Q3 2016 and held it in 12 quarters. The position peaked at $3.18M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Schonfeld Strategic Advisors reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 242,952 Astria Therapeutics shares in Q1 2026, an estimated $3.18M.
- Schonfeld Strategic Advisors first reported a position in Astria Therapeutics in Q3 2016 and held it in 12 quarters.
- Schonfeld Strategic Advisors's Astria Therapeutics position peaked at $3.18M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.